KOSDAQBiotech & Pharma387690

Remedi

₩10,240▲ 1.39%2026-11-18 close
Market Cap
₩78.1B
Turnover
₩1.1B
Volume
110K
Shares out.
7.6M
PER
—
PBR
—
EPS
—
Dividend Yield
—

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-11-18 close

01

Report overview

A profitable X-ray maker in its proof phase

Remedi turned operating profit positive in the first nine months of 2026, but a net loss and cumulative sales well below its earlier outlook leave the conversion of follow-on products and overseas tenders as the key checkpoints.

  1. 1

    Cumulative revenue for the first nine months of 2026 was KRW 3.8 billion, up 139.4% year on year.

  2. 2

    Operating profit for the same period was KRW 281 million, a swing to profit, while the net loss was KRW 364 million, a swing to loss.

  3. 3

    Medical portable X-ray products and related goods reached 92.7% of sales in the first quarter of 2026, up from 87.3% in 2025.

  4. 4

    The 2026 sales forecast presented at the IPO was KRW 24.2 billion, and cumulative third-quarter sales in the DART filing equal about 16% of that figure.

  5. 5

    According to AlphaSquare, the 52-week high was KRW 34,650 and the low was KRW 6,980, while the current price is KRW 10,040 with a market capitalization of KRW 76.6 billion.

02

Business structure

Remedi was founded in July 2012 as a radiation technology company and develops and supplies medical portable X-ray units, industrial non-destructive testing (NDT) equipment and core X-ray components, built on low-dose, miniaturized and high-definition X-ray technology.

Medical portable X-ray devices form the core of sales, and the share of medical X-ray products and goods rose from 67.2% in 2023 to 86.4% in 2024 and 87.3% in 2025, reaching 92.7% in the first quarter of 2026.

The flagship KA6 is a 2.4kg ultra-portable unit used in hospital wards, emergency sites and mobile screening, and it is sold in 34 countries.

Follow-on models include the higher-performance XCAM6 and the next-generation XCAM10, which the company positions as a high-end product for home-care markets in advanced economies.

In industrial NDT, the company has supplied battery inspection equipment to LG Energy Solution, but management says the contribution to current sales and operating profit is limited.

The company says more than 90% of total sales come from overseas, with India the largest country by sales and growing sales in Indonesia and the Philippines. It sells through 83 local distributors across 43 countries and holds 83 approvals covering seven portable X-ray products.

Against competing units weighing 3.5 to 7.4kg, the company says KA6 is lighter and can take 270 to 290 exposures per charge. On the production side, the first plant has capacity of 3,500 to 4,000 units, and the second plant has been acquired while its production and automation equipment is being built.

03

Recent trends

Remedi recorded 2025 full-year revenue of KRW 14.6 billion, operating profit of KRW 2.8 billion and net income of KRW 5.1 billion. Revenue rose 8.8% from KRW 13.4 billion in 2024, and operating profit rose 191.3% from KRW 900 million in 2024.

The company posted an operating loss of KRW 2.3 billion in 2023 before returning to profit in 2024, and the profit margin widened further in 2025. In the cumulative DART filing for the first nine months of 2026, revenue was KRW 3.8 billion, up 139.4% year on year.

Operating profit for the same period was KRW 281 million, a swing to profit, while the net loss was KRW 364 million, a swing to loss. Operating profit and net income therefore moved in different directions over the period.

At the IPO, the company presented a 2026 revenue forecast of KRW 24.2 billion, and the cumulative sales in the filing equal about 16% of that figure. The share price has been volatile since the July 2026 listing.

According to AlphaSquare, the 52-week high was KRW 34,650 and the low was KRW 6,980, and the close on September 29, 2026 was KRW 19,760, down 14.83%.

According to Daum Finance, the close on October 29, 2026 was KRW 14,070, and the current price is KRW 10,040, up 1.72% on the day, with a market capitalization of KRW 76.6 billion.

04

Outlook

Future earnings will depend on how far the mid-term plans presented at the IPO are realized. The company projected revenue of KRW 40.6 billion for 2027 and KRW 63.2 billion for 2028, and the 2028 medical revenue estimate of KRW 59.4 billion assumes expanded sales of the XCAM series, package components and AI software.

Current sales remain concentrated in KA6-based products and goods, so converting follow-on products into revenue is the central variable. The XCAM10 is expected to be saleable from 2027, and that projection assumes launch and market adoption rather than proven results.

On capacity, medical portable X-ray production capacity in the first half of 2026 reached 3,000 units, up from 2,000 units for full-year 2025. The company has stated its plan to expand public tenders in Indonesia, the Philippines and Bangladesh as three core hubs.

Management has said the 2028 estimate assumes expanded sales of KA6-based package solutions rather than standalone AI software sales.

The 2026 full-year results will be confirmed through the annual report filing, and the fourth-quarter sales trend will show how the gap to the full-year forecast is narrowing or widening.

Industrial NDT and battery inspection equipment are presented as mid-to-long-term growth axes, but their current contribution remains limited.

05

Bull factors

Expanding overseas public tenders

Remedi was selected for India's health ministry infrastructure program, installing its products in 2,301 public hospitals and operating them for six years. KA6 was adopted in Japan's government support program for Ukraine and the company also won a JICA public procurement tender.

The company plans to widen participation in government-led tuberculosis programs in Indonesia, the Philippines and Bangladesh.

Product differentiation and approval base

The company says KA6 weighs 2.4kg, lighter than competing units at 3.5 to 7.4kg, and can take 270 to 290 exposures per charge. It holds 83 approvals across seven portable X-ray products and works with 83 local distributors in 43 countries.

Its selection as a portable X-ray unit in a NASA spacecraft project is cited as evidence of technical credibility.

Capacity expansion and profit turn

Medical portable X-ray capacity in the first half of 2026 reached 3,000 units, up from 2,000 units for full-year 2025. The company attributes the increase to automation equipment and process efficiency.

Cumulative operating profit for the first nine months of 2026 was KRW 281 million, a swing to profit, which may serve as a starting point for converting capacity into earnings.

06

Bear factors

Concentration in medical X-ray and KA6

Medical X-ray-related products and goods reached 92.7% of sales in the first quarter of 2026. Current revenue is concentrated in KA6-based equipment and related goods. Heavy reliance on a single product family or large overseas procurement orders can increase earnings volatility when order timing shifts.

Gap between IPO forecast and cumulative results

The 2026 revenue forecast presented at the IPO was KRW 24.2 billion, while cumulative revenue for the first nine months of 2026 was KRW 3.8 billion.

Of the KRW 59.4 billion medical revenue estimate for 2028, KA6 accounts for KRW 17.6 billion, or about 29.6%, and the remainder assumes expansion of XCAM, packages and AI software. These amounts are estimates rather than proven results.

Net loss and valuation debate

The cumulative net loss for the first nine months of 2026 was KRW 364 million, a swing to loss. Press coverage of the IPO said the pricing relied heavily on 2028 earnings. Reports at the pricing stage put the PER at about 33 times 2025 net income, and some commentators described the valuation as aggressive.

07

Risk factors

Macro

More than 90% of the company's sales come from overseas, so changes in public health budgets and government procurement timing in developing countries directly affect results. India is the largest market, which increases exposure to policy or procurement changes in a single country. Currency movements and inventory flows at overseas distributors can add quarterly volatility.

Regulatory

Remedi holds 83 approvals covering seven portable X-ray products, and sales in each country depend on maintaining medical device registrations. Entry into home-care and mobile diagnostics in the United States, Europe and Japan depends on additional approvals and sales experience. Changes in approval timelines or requirements could affect the launch timing of new products.

Execution

Follow-on products such as the XCAM10 are assumed to begin sales in 2027, so launch delays or slow market adoption would affect the mid-term estimates. Industrial NDT and battery inspection are long-term growth axes but contribute little to current results. Whether expanded capacity converts into orders and profit is the central execution question.

08

Overall view

Remedi showed improving profitability through a wider 2025 profit and a swing to positive cumulative operating profit in the first nine months of 2026. However, the cumulative net loss of KRW 364 million and cumulative revenue of KRW 3.8 billion remain early-stage results relative to the forecast presented at the IPO.

The business is concentrated in medical portable X-ray equipment, particularly KA6, with medical X-ray-related products reaching 92.7% of sales in the first quarter of 2026. Strengths cited include public tender wins in India and Japan, expanded capacity and 83 approvals.

Weaknesses include the conversion of follow-on products into sales, reliance on overseas public procurement, and whether the 2028 estimates underpinning the IPO valuation can be verified.

The current market capitalization of KRW 76.6 billion and the price of KRW 10,040 sit well below the 52-week high of KRW 34,650 reached after the July 2026 listing. The 2026 full-year results and whether XCAM10 sales begin are the key facts to be confirmed next.

09

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 9 more articles and sources
  1. m.news.nate.com
  2. m.news.nate.com
  3. m.news.nate.com
  4. sedaily.com
  5. bloter.net
  6. m.news.nate.com
  7. supple.kr
  8. alphasquare.co.kr
  9. m.finance.daum.net

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis